RT Journal Article
SR Electronic
T1 Cohort Profile: The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.09.22280886
DO 10.1101/2022.10.09.22280886
A1 Stærke, Nina Breinholt
A1 Reekie, Joanne
A1 Johansen, Isik S.
A1 Nielsen, Henrik
A1 Benfield, Thomas
A1 Wiese, Lothar
A1 Søgaard, Ole Schmeltz
A1 Tolstrup, Martin
A1 Iversen, Kasper Karmark
A1 Tarp, Britta
A1 Larsen, Fredrikke Dam
A1 Larsen, Lykke
A1 Lindvig, Susan Olaf
A1 Holden, Inge Kristine
A1 Iversen, Mette Brouw
A1 Knudsen, Lene Surland
A1 Fogh, Kamille
A1 Jakobsen, Marie Louise
A1 Traytel, Anna
A1 Østergaard, Lars
A1 Lundgren, Jens
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/10/10/2022.10.09.22280886.abstract
AB Purpose The ENFORCE cohort is a national Danish prospective cohort of adults who received a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as part of the Danish National SARS-CoV-2 vaccination program. It was designed to investigate the long-term effectiveness, safety and durability of SARS-CoV-2 vaccines used in Denmark.Participants A total of 6943 adults scheduled to receive a SARS-CoV-2 vaccine in the Danish COVID-19 Vaccination Program were enrolled in the study prior to their first vaccination. Participants will be followed for a total of two years with five predetermined follow-up visits and additional visits in relation to any booster vaccination. Serology measurements are performed after each study visit. T-cell immunity is evaluated at each study visit for a subgroup of 699 participants. Safety information is collected from participants at visits following each vaccination. Data on hospital admissions, diagnoses, deaths and SARS-CoV-2 polymerase chain reaction (PCR) results are collected from national registries throughout the study period. The median age of participants was 64 years (IQR 53-75), 56.6% were females and 23% were individuals with an increased risk of a serious course of COVID-19. A total of 340 (4.9%) participants tested positive for SARS-CoV-2 spike IgG at baseline.Findings to date Results have been published on risk factors for humoral hyporesponsiveness and non-durable response to SARS-CoV-2 vaccination, the risk of breakthrough infections at different levels of SARS-CoV-2 spike IgG by viral variant, and on the antibody neutralizing capacity against different SARS-CoV-2 variants following primary and booster vaccinations.Future plans The ENFORCE cohort will continuously generate studies investigating immunological response, effectiveness, safety and durability of the SARS-CoV-2 vaccines.Registration clinicaltrials.gov identifier: NCT04760132.Strengths and limitations- The ENFORCE study combines repeated detailed SARS-CoV-2 specific immunological measurements prior to, and throughout the course of SARS-CoV-2 vaccination, with register-based follow-up of safety data and microbiological test results.- The ENFORCE cohort includes a large proportion of elderly participants and participants with concomitant diseases.- The three vaccine groups display a high degree of variation in demographic factors and distribution across risk groups, due to the prioritization of specific vaccines to risk groups during the primary roll out of the SARS-CoV-2 vaccination program.Competing Interest StatementNS declares to have served as investigator on studies sponsored by Pfizer, Gilead, Bavarian and Sanofi Pasteur. HN declares receiving a grant from Novo Nordisk Foundation and to have been on advisory boards for MSD and GSK. TB declares receipt of unrestricted research or travel grants from GSK, Pfizer, Gilead Sciences, MSD; and being principal investigator on trials conducted by Boehringer Ingelheim, Roche, Novartis, Kancera, Pfizer, MSD and Gilead; Board member on Pentabase, and advisory board member for MSD, Gilead, Pfizer, GSK, Janssen and AstraZeneca; consulting fees from GSK and Pfizer; receiving donation of study drug from Eli Lilly; and receiving honorarium for lectures from GSK, Pfizer, Gilead Sciences, Boehringer Ingelheim, Abbvie and AstraZeneca.Funding StatementThis study was funded by the Danish Ministry of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics Committees at Region Midtjylland gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata may be made available to scientists upon approval of an application sent to the ENFORCE Scientific Steering Committee and further approval by relevant authorities. Applications for data must be sent to enforce.rigshospitalet{at}regionh.dk. Detailed information about data access may be found here: https://chip.dk/Research/Studies/ENFORCE/Study-Governance.